Biomarker predictors for immunotherapy benefit in breast: beyond PD-L1

JL James, JM Balko - Current breast cancer reports, 2019 - Springer
Abstract Purpose of Review Immune checkpoint blockade (ICB) has changed the clinical
course of multiple cancer types and durable responses have now been observed in breast …
被引用次数：8 相关文章

Biomarker predictors for immunotherapy benefit in breast: beyond PD-L1.

JL James, JM Balko - Current Breast Cancer Reports, 2019 - europepmc.org
Biomarker predictors for immunotherapy benefit in breast: beyond PD-L1. - Abstract - Europe
PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers …

Biomarker predictors for immunotherapy benefit in breast: beyond PD-L1

JL James, JM Balko - Current breast cancer reports, 2019 - pubmed.ncbi.nlm.nih.gov
Purpose of review Immune checkpoint blockade (ICB) has changed the clinical course of
multiple cancer types and durable responses have now been observed in breast cancer …
[HTML] nih.gov

[HTML][HTML] Biomarker predictors for immunotherapy benefit in breast: beyond PD-L1

JL James, JM Balko - Current breast cancer reports, 2019 - ncbi.nlm.nih.gov
Biomarker predictors for immunotherapy benefit in breast: beyond PD-L1 - PMC Back to Top
Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main …